Determinants of Response to Cardiac Resynchronization Therapy.

J Innov Card Rhythm Manag

The Demoulas Center for Cardiac Arrhythmias, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Published: May 2022

Cardiac resynchronization therapy (CRT) is a well-established treatment modality for ambulatory patients with heart failure (HF) who have prolonged QRS, left bundle branch block, reduced left ventricular (LV) ejection fraction, and New York Heart Association class II-IV. CRT has been shown to induce reverse LV remodeling and improve HF symptoms and clinical outcomes. About one-third of CRT recipients are considered non-responders. Patient selection, LV lead location, LV lead selection, multipoint pacing, and optimization of the atrioventricular and ventriculo-ventricular intervals were all shown to be associated with a better CRT response rate. Herein, we review the determinants of CRT response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154012PMC
http://dx.doi.org/10.19102/icrm.2022.130503DOI Listing

Publication Analysis

Top Keywords

cardiac resynchronization
8
resynchronization therapy
8
crt response
8
crt
5
determinants response
4
response cardiac
4
therapy cardiac
4
therapy crt
4
crt well-established
4
well-established treatment
4

Similar Publications

Objective: To evaluate systematically the feasibility and effectiveness of His Bundle Pacing (HBP) for cardiac resynchronization therapy.

Methods: A comprehensive search was conducted in PubMed, EMbase, WOS, Cochrane Library, Medline, and SinoMed for studies published between December 2003 and December 2023. Primary clinical outcomes included implantation success, QRS wave duration, pacing threshold, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), New York Heart Association (NYHA) cardiac function class, and complications.

View Article and Find Full Text PDF

Background: Accurate prediction for survival in individualized patients with cardiac resynchronization therapy with a defibrillator (CRT-D) is difficult.

Methods: We analyzed the New Japan cardiac device treatment registry (JCDTR) database to develop a survival prediction model for CRT-D recipients.

Results: Four hundred and eighty-two CRT-D recipients, at the implantation year 2018-2021, with a QRS width ≥120 ms and left ventricular ejection fraction (LVEF) ≤35% at baseline, were analyzed.

View Article and Find Full Text PDF

Background: The prevalence rates of heart failure (HF) and hyperpolypharmacy have increased with the aging population. While a negative impact of hyperpolypharmacy on HF clinical outcomes has already been reported, the effects of hyperpolypharmacy on patients with advanced HF with reduced ejection fraction (HFrEF) undergoing cardiac resynchronization therapy (CRT) remain unclear.

Methods: We retrospectively evaluated data from 147 patients with advanced HFrEF who underwent CRT between March 2004 and June 2020.

View Article and Find Full Text PDF

Congenital heart disease (CHD) is the most common congenital anomaly in newborns. Advances in catheter and surgical techniques led to the majority of these patients surviving into adulthood, leading to evolving challenges due to the emergence of long-term complications such as arrhythmias. Interventional electrophysiology (EP) has had remarkable advances over the last few decades, and various techniques and devices have been explored to treat adult patients with CHD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!